High expression of CCDC25 in cholangiocarcinoma tissue samples

Proungvitaya, Siriporn; Klinthong, Wachiraya; Proungvitaya, Tanakorn; Limpaiboon, Temduang; Jearanaikoon, Patcharee; Roytrakul, Sittiruk; Wongkham, Chaisiri; Nimboriboonporn, Anongporn; Wongkham, Sopit

doi:10.3892/ol.2017.6446

Cited by 11 publications

(15 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A previous study reported that CCDC25 was upregulated in CCA tissues when compared with adjacent non-CCA tissues (10). In the present study, a quantitative dot blot assay based on the standard curve created using standard CCDC25 protein was used to reveal that the serum CCDC25 level of patients with CCA was significantly higher compared with that of HCs and patients with BBD.…”

Section: Discussionmentioning

confidence: 96%

“…Furthermore, the mechanisms regulating CCDC25 protein expression in CCA cells require further investigation. As CCDC25 was identified as a potential functional protein from the genome database (12–15) and only recombinant protein and antibody against it were produced, the biological and physiological functions of CCDC25 is almost unknown (10). Overexpression by gene transfection or depressed production by gene silencing using CCA cells will elucidate the biological role of CCDC25 and possible regulatory mechanisms of its expression.…”

Section: Discussionmentioning

confidence: 99%

“…A recent study revealed that CCDC25 could be detected in CCA tissues but not in adjacent normal tissues, and that migration of CCA cells is activated by bile acids, especially cholic acid, in association with upregulation of CCDC25 (10). However, whether CCDC25 is upregulated and released in the sera of patients with CCA remains unknown.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Serum coiled‑coil domain containing 25 protein as a potential screening/diagnostic biomarker for cholangiocarcinoma

et al. 2019

Self Cite

View full text Add to dashboard Cite

Coiled-coil domain containing 25 (CCDC25) was previously reported to be upregulated in cholangiocarcinoma (CCA) tissues compared with adjacent normal tissues. The present study investigated whether serum CCDC25 level may be used as a potential marker for the diagnosis of CCA. Bioinformatics tools were used to reveal that CCDC25 is secreted into plasma/serum via a non-conventional pathway, which secretes proteins independently from the endoplasmic reticulum/golgi complex, but is yet to be fully elucidated. Subsequently, the CCDC25 levels in the sera of patients with CCA (n=141), patients with benign biliary disease (BBD; n=53) and healthy controls (HC; n=72) were measured using a quantitative dot blot assay based on the standard curve created using recombinant CCDC25 protein. The results demonstrated that the serum CCDC25 level in the CCA group (0.28±0.06 ng/µl) was significantly higher compared with that in the BBD (0.15±0.03 ng/µl) or HC (0.0017±0.0008 ng/µl) groups. Serum CCDC25 level provided an improved resolution (P=0.0001) compared with carcinoembryonic antigen (P=0.098) or carbohydrate antigen 19-9 (P=0.271) for the differential diagnosis between BBD and CCA. Receiver operating characteristic curve analysis revealed high sensitivity and specificity of serum CCDC25 level to differentiate between patients with CCA and HC (93.0 and 100%, respectively), and also to differentiate between patients with CCA and patients with BBD (75.0 and 84.0%, respectively). CCDC25 expression was further investigated in 23 CCA tissues, and CCDC25 expression in cancer tissues was moderately correlated with the serum CCDC25 level (r 2 =0.52, P=0.01). Among patients with CCA, serum CCDC25 level was significantly higher in patients with non-metastatic CCA compared with patients with metastatic CCA. Correspondingly, a higher serum CCDC25 level was associated with a longer overall survival time in patients with CCA. In conclusion, serum CCDC25 level may be a promising screening and diagnostic marker for the differential diagnosis of CCA.

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Serum coiled‑coil domain containing 25 protein as a potential screening/diagnostic biomarker for cholangiocarcinoma

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…Treatment with CA and DCA as BAs induces the migration of CC cells, and CA- and DCA-mediated protein expression profiles identify CCD25 and is significantly upregulated in patients with CC. Also, CCD25 has been associated with the son of sevenless homolog 1 (SOS1) and growth factor receptor-bound protein 2 (GRB2), which are involved in EGFR signaling [ 85 ].…”

Section: Modulators Of Egfr Family Activation In the Progression Omentioning

confidence: 99%

ErBb Family Proteins in Cholangiocarcinoma and Clinical Implications

Jin

2020

JCM

View full text Add to dashboard Cite

The erythroblastic leukemia viral oncogene homolog (ErBb) family consists of the receptor tyrosine kinases (RTK) epidermal growth factor receptor (EGFR; also called ERBB1), ERBB2, ERBB3, and ERBB4. This family is closely associated with the progression of cholangiocarcinoma (CC) through the regulation of cellular networks, which are enhanced during tumorigenesis, metastasis, and chemoresistance. Additionally, the constitutive activation of cellular signaling by the overexpression and somatic mutation-mediated alterations conferred by the ErBb family on cholangiocarcinoma and other cancers enhances tumor aggressiveness and chemoresistance by contributing to the tumor microenvironment. This review summarizes the recent findings on the molecular functions of the ErBb family and their mutations during the progression of cholangiocarcinoma. It also discusses the developments and applications of various devising strategies for targeting the ErBb family through different inhibitors in various stages of clinical trials, which are essential for improving targeted clinical therapies.

show abstract

“…Recently, we found that CCDC25 is overexpressed in CCA tissues [ 6 ] and serum CCDC25 level of CCA patients is significantly higher than that of healthy controls [ 7 ]. Moreover, recently one of our colleagues (R.C.)…”

Section: Introductionmentioning

confidence: 99%

Kallikrein-11, in Association with Coiled-Coil Domain Containing 25, as a Potential Prognostic Marker for Cholangiocarcinoma with Lymph Node Metastasis

et al. 2021

Self Cite

View full text Add to dashboard Cite

Cholangiocarcinoma (CCA) is a malignancy arising from cholangiocytes. Currently, the treatment and prognosis for CCA are mostly poor. Recently, we have reported that coiled-coil domain containing 25 (CCDC25) protein level in the sera may be a diagnostic marker for CCA. Subsequently, we identified three binding proteins of CCDC25 and found that kallikrein-11 (KLK11) expression was highest among those binding proteins. In this study, we investigated CCDC25 and KLK11 expression in CCA and adjacent normal tissues (n = 18) using immunohistochemistry. The results demonstrated that the expressions of CCDC25 and KLK11 in CCA tissues were both significantly higher than the adjacent tissues (p < 0.001 and p = 0.001, respectively). Then, using GEPIA bioinformatics analysis, KLK11 mRNA was significantly overexpressed in CCA tumor tissues compared with normal tissues (p < 0.05). Moreover, CCDC25 expression was positively correlated with KLK11 expression in CCA with lymph node metastasis (p = 0.028, r = 0.593). An analysis for the interaction of KLK11 with CCDC25 and other proteins, using STRING version 11.0, revealed that CCDC25 and KLK11 correlated with metastasis-related proteins. In addition, Kaplan-Meier survival curve analysis revealed that a high expression of KLK11 was associated with the poor prognosis of CCA. In conclusion, KLK11 is, as a binding protein for CCDC25, possibly involved in the metastatic process of CCA. KLK11 may be used as a prognostic marker for CCA.

show abstract

High expression of CCDC25 in cholangiocarcinoma tissue samples

Cited by 11 publications

References 22 publications

Serum coiled‑coil domain containing 25 protein as a potential screening/diagnostic biomarker for cholangiocarcinoma

Serum coiled‑coil domain containing 25 protein as a potential screening/diagnostic biomarker for cholangiocarcinoma

ErBb Family Proteins in Cholangiocarcinoma and Clinical Implications

Kallikrein-11, in Association with Coiled-Coil Domain Containing 25, as a Potential Prognostic Marker for Cholangiocarcinoma with Lymph Node Metastasis

Contact Info

Product

Resources

About